Virginie Giroux, Canada
Merck & Co., Inc., Canada Outcomes researchPoster Author Of 1 e-Poster
HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CANADIAN CHILDREN
Author Of 1 Presentation
HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CANADIAN CHILDREN (ID 706)
Abstract
Background
A 15-valent pneumococcal conjugate vaccine (V114) containing PCV13 serotypes and 22F/33F is under development. This study quantifies the health and economic burden of V114-type pneumococcal disease in Canadian children.
Methods
V114-type invasive pneumococcal disease (IPD) and acute otitis media (AOM) cases were simulated in a single, unvaccinated cohort from birth to 20 years with a Markov model. In the pre-PCV scenario, pre-PCV7 epidemiological inputs were used. In the post-PCV scenario, pre-PCV7, pre-PCV13 and current-day inputs were used to estimate PCV7, PCV13 not PCV7 (PCV13-PCV7), and 22F/33F disease, respectively. Costs were estimated from a societal perspective and discounted at 1.5%.
Results
In the pre-PCV scenario, 600 V114-type IPD cases were attributable to PCV7 serotypes (n=535, 89%), PCV13-PCV7 serotypes (n=56, 9%), and 22F/33F (n=9, 2%); 715,642 V114-type AOM outpatient visits were attributable to PCV7 serotypes (n=519,286, 73%), PCV13-PCV7 serotypes (n=189,864, 27%), and 22F/33F (n=6,491, 1%). Total costs for V114-type IPD and AOM were CA$274 million. In the post-PCV scenario, PCV13-PCV7 serotypes increased, specifically serotypes 3, 19A and 7F for IPD, and 19A for AOM.
Conclusions
PCV7 serotypes cause most pneumococcal morbidity and are important to retain in PCVs. Select PCV13-PCV7 serotypes also contribute to the disease burden. Including non-vaccine serotypes can prevent additional disease burden.